Market Overview

Santarus, VeroScience Announce Publication of New CYCLOSET Cardiovascular Data

Santarus,
(NASDAQ: SNTS) and VeroScience, LLC today announced that new
analyses of cardiovascular endpoint data from a previously disclosed
52-week, randomized safety study with CYCLOSET®
(bromocriptine mesylate) tablets were published in the Journal of the
American Heart Association (JAHA), an online publication. CYCLOSET
is a unique, quick release form of bromocriptine, a dopamine D2 receptor
agonist, and is approved as an adjunct to diet and exercise to improve
glycemic control in adults with type 2 diabetes mellitus.

In this safety study, a total of 3,070 patients on stable doses of up to
two antidiabetes medications (including insulin) with HbA1c ≤ 10.0
(average baseline HbA1c=7.0) were randomized 2:1 to CYCLOSET (1.6 to

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (SNTS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters